UBS’s Sonoma Pharmaceuticals SNOA Stock Holding History

UBS’s Portfolio SNOA Stock Details SNOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$5K	Sell	2 -4	-67%	-$9.3K	﹤0.01%	9482
2014 Q2	$17K	Buy	6 +4	+200%	+$11.8K	﹤0.01%	8278
2014 Q1	$7K	Hold	2	–	–	﹤0.01%	9261
2013 Q4	$6K	Sell	2 -2	-50%	-$5.32K	﹤0.01%	9446
2013 Q3	$10K	Buy	4 +2	+100%	+$4.87K	﹤0.01%	8824
2013 Q2	$6K	Buy	+2	New	+$7.15K	﹤0.01%	9131

Other funds holding SNOA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

UBS's SNOA Position: Q3 2014 in Review

UBS reduced its Sonoma Pharmaceuticals (SNOA) stake by 67% in Q3 2014, selling an estimated $9.3K and leaving 2 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #9482.

UBS first reported a position in SNOA in Q2 2013 and has held it in 6 quarters since. The position peaked at $17K in Q2 2014. 12 funds tracked by Wall St. Rank hold SNOA as of Q3 2014.

UBS held 2 shares of Sonoma Pharmaceuticals worth $5K as of Q3 2014.
UBS sold 4 Sonoma Pharmaceuticals shares in Q3 2014, an estimated $9.3K.
Sonoma Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9482 holding.
UBS first reported a position in Sonoma Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
UBS's Sonoma Pharmaceuticals position peaked at $17K in Q2 2014.
12 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.